Cinacalcet

The dosage of Cinacalcet must be highly individualized and titrated based on the patient's serum calcium and PTH levels. Healthcare providers typically start with a low dose and adjust it every 2 to 4 weeks.

• Secondary Hyperparathyroidism in CKD on Dialysis: The standard starting dose for adults is 30 mg once daily. The dose may be titrated to 60 mg, 90 mg, 120 mg, or a maximum of 180 mg once daily to achieve the target PTH levels (typically 150-300 pg/mL for patients on dialysis).
• Parathyroid Carcinoma: The recommended starting dose is 30 mg twice daily. The dose can be titrated every 2 to 4 weeks through sequential doses of 30 mg twice daily, 60 mg twice daily, 90 mg twice daily, and 90 mg three or four times daily as necessary to normalize serum calcium levels.
• Primary Hyperparathyroidism: The starting dose is 30 mg twice daily. Similar to parathyroid carcinoma, the dose is adjusted based on the patient's calcium response, typically ranging from 30 mg twice daily to 90 mg twice daily.

Cinacalcet is generally not recommended for use in pediatric patients with CKD unless under the strict guidance of a pediatric nephrologist. In 2013, the FDA issued a safety communication following the death of a pediatric patient in a clinical trial, which was linked to severe hypocalcemia. While some formulations (granules) are approved for children aged 3 and older in specific jurisdictions (like the EU) for secondary HPT, its use in the United States remains largely restricted to adults. If prescribed for a child, the dose is based on body weight and must be monitored with extreme frequency.

Renal Impairment

No dosage adjustment of Cinacalcet is necessary for patients with renal impairment, as the drug is primarily used in patients already suffering from advanced kidney disease (Stage 5 CKD on dialysis).

Hepatic Impairment

In patients with moderate to severe hepatic impairment (liver disease), Cinacalcet exposure (AUC) can be 2 to 4 times higher than in patients with normal liver function. Healthcare providers will monitor these patients very closely, and dose titration may occur more slowly.

Elderly Patients

Clinical studies did not identify significant differences in safety or efficacy between patients over 65 and younger patients. However, since elderly patients are more likely to have decreased hepatic or cardiac function, the starting dose should be approached with caution.

To ensure the best results and minimize side effects, follow these guidelines:

• Take with Food: Cinacalcet should be taken with food or shortly after a meal. This increases the amount of medicine your body absorbs and can help reduce the common side effect of nausea.
• Consistency: Try to take your dose at the same time every day to maintain steady levels in your bloodstream.
• Swallow Whole: Tablets should be swallowed whole. Do not crush, chew, or break the tablets, as this can affect how the medication is released into your system.
• Storage: Store the medication at room temperature (20°C to 25°C or 68°F to 77°F) in a dry place away from direct sunlight.

If you miss a dose of Cinacalcet, take it as soon as you remember, provided it is not too close to your next scheduled dose. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Never take two doses at once to make up for a missed one. If you miss several doses, contact your healthcare provider for instructions, as your calcium levels may need to be checked.

An overdose of Cinacalcet can lead to dangerously low levels of serum calcium (hypocalcemia). Symptoms of an overdose may include tingling in the fingers or toes, muscle aches, cramping, or seizures. In the event of a suspected overdose, seek emergency medical attention immediately. Treatment typically involves the administration of intravenous calcium and close cardiac monitoring.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, as this can lead to a rapid rebound in PTH and calcium levels.

Cinacalcet is known to cause gastrointestinal and mineral-related side effects in a significant portion of patients. The most frequently reported adverse reactions include:

• Nausea and Vomiting: These are the most common reasons patients discontinue the medication. Nausea usually occurs shortly after taking the dose and may diminish over time as the body adjusts. Taking the medication with a full meal is the most effective way to manage this.
• Diarrhea: This can occur in up to 20% of patients. It is generally mild but should be reported if it becomes persistent.
• Myalgia (Muscle Pain): Patients often report generalized muscle aches or soreness, which may be related to the rapid shifts in mineral balance within the muscle tissues.
• Hypocalcemia: Low blood calcium is a direct pharmacological effect of the drug. While often asymptomatic if mild, it is a primary concern for healthcare providers.

• Dizziness and Vertigo: Some patients may feel lightheaded, especially when standing up quickly.
• Hypotension (Low Blood Pressure): This can occur, particularly in patients with underlying heart conditions or those on dialysis.
• Upper Respiratory Infections: A slightly increased incidence of cough and sore throat has been noted in clinical trials.
• Hypocalcemia-related Paresthesia: A 'pins and needles' sensation, usually felt around the mouth or in the extremities.

• Seizures: The threshold for seizures is lowered when blood calcium levels drop. This is a rare but serious occurrence.
• Worsening Heart Failure: In patients with pre-existing low cardiac function, the electrolyte shifts caused by Cinacalcet may exacerbate heart failure symptoms.
• QT Prolongation: Changes in the heart's electrical rhythm can occur as a secondary result of low calcium levels.

> Warning: Stop taking Cinacalcet and call your doctor immediately or seek emergency care if you experience any of the following symptoms of severe hypocalcemia:

• Tetany and Muscle Spasms: Severe, uncontrollable muscle contractions or 'locking' of the muscles in the hands, feet, or face.
• Seizures: Any new onset of convulsing or loss of consciousness.
• Cardiac Arrhythmias: Feeling like your heart is skipping beats, racing, or fluttering.
• Mental Status Changes: Sudden confusion, anxiety, or hallucinations.
• Severe Paresthesia: Intense numbness or tingling that does not go away.

• Adynamic Bone Disease: If PTH levels are suppressed too aggressively for a long period, the natural process of bone turnover may slow down too much. This makes bones brittle and less able to repair themselves, increasing the risk of fractures. This is why doctors monitor PTH levels to ensure they do not fall below the recommended range (usually 150 pg/mL for dialysis patients).
• Vascular Calcification Changes: While Cinacalcet is intended to reduce the risk of calcification, long-term shifts in the calcium-phosphorus product must be managed to ensure cardiovascular health.

As of 2026, there are no FDA black box warnings for Cinacalcet. However, the FDA has issued several 'Warnings and Precautions' regarding the risk of severe hypocalcemia, particularly in pediatric populations and patients with seizure disorders. The medication is contraindicated in patients whose serum calcium is below the lower limit of the normal range at the start of therapy.

Report any unusual symptoms, especially muscle cramps or heart palpitations, to your healthcare provider immediately. Regular blood tests are the only way to catch these side effects before they become dangerous.

Cinacalcet is a potent medication that significantly alters mineral metabolism. The most critical safety concern is the risk of hypocalcemia (low blood calcium). Because calcium is vital for muscle contraction, nerve signaling, and heart function, low levels can lead to life-threatening complications. Patients must be committed to regular blood monitoring as scheduled by their nephrologist or endocrinologist.

No FDA black box warnings for Cinacalcet. However, the clinical community treats the risk of hypocalcemia with a level of caution similar to a boxed warning, particularly regarding its use in children.

Hypocalcemia and Seizure Risk

Cinacalcet lowers the threshold for seizures. Patients with a pre-existing history of seizure disorders are at a higher risk when taking this medication. If blood calcium levels drop significantly, even patients without a history of seizures may experience them. It is imperative that serum calcium is measured within one week of starting the drug or adjusting the dose.

Cardiovascular Effects (QT Prolongation)

Decreases in serum calcium can prolong the QT interval on an electrocardiogram (ECG). This can lead to a dangerous heart rhythm known as ventricular arrhythmia. Patients with 'Long QT Syndrome' or those taking other medications that affect the heart rhythm must be monitored with extreme care.

Adynamic Bone Disease

As mentioned previously, excessively low PTH levels (e.g., <100-150 pg/mL) can lead to adynamic bone disease, a condition where bone remodeling stops. This increases the risk of 'hungry bone syndrome' and fractures. If PTH levels fall below the target range, the dose of Cinacalcet must be reduced or discontinued.

Gastrointestinal Bleeding

There have been rare reports of gastrointestinal bleeding in patients taking calcimimetics, though a direct causal link is still being studied. Patients with a history of peptic ulcers should inform their doctor.

To ensure safety, the following monitoring schedule is typically employed:

• Serum Calcium: Should be measured within 1 week after the first dose or any dose adjustment. Once a stable dose is reached, calcium should be measured monthly.
• PTH (Parathyroid Hormone): Should be measured 1 to 4 weeks after starting or adjusting the dose. Once stable, it is monitored every 1 to 3 months.
• Phosphorus: Usually monitored alongside calcium to prevent mineral imbalances.

Cinacalcet can cause dizziness or seizures in some patients. You should not drive or operate heavy machinery until you know how this medication affects you, especially during the first few weeks of treatment or after a dose increase.

There is no direct chemical interaction between alcohol and Cinacalcet. However, alcohol can cause dehydration and electrolyte imbalances, which may complicate the management of calcium levels. Furthermore, alcohol can worsen the nausea and dizziness associated with Cinacalcet. It is best to limit alcohol consumption while on this medication.

Do not stop taking Cinacalcet suddenly. Stopping the medication can cause a rapid 'rebound' increase in PTH and calcium levels, which can be dangerous. If the medication must be stopped, your doctor will provide a tapering schedule and monitor your blood work closely during the transition.

> Important: Discuss all your medical conditions, especially liver disease, heart rhythm problems, or a history of seizures, with your healthcare provider before starting Cinacalcet.

While there are few absolute contraindications for drug combinations, Cinacalcet should not be used in combination with Etelcalcetide (Parsabiv), which is an intravenous calcimimetic. Using both together significantly increases the risk of severe, life-threatening hypocalcemia. Patients must undergo a 'washout period' (usually 4 weeks) when switching from Cinacalcet to Etelcalcetide.

CYP2D6 Substrates

Cinacalcet is a strong inhibitor of the liver enzyme CYP2D6. This means it can slow down the breakdown of other drugs that rely on this enzyme, leading to toxic levels of those drugs in the blood. Examples include:

• Tricyclic Antidepressants (TCAs): Such as amitriptyline or nortriptyline.
• Antipsychotics: Such as thioridazine.
• Antiarrhythmics: Such as flecainide or propafenone.
• Beta-blockers: Such as metoprolol.

Strong CYP3A4 Inhibitors

Drugs that inhibit the CYP3A4 enzyme can prevent the breakdown of Cinacalcet, leading to higher levels of Cinacalcet and an increased risk of side effects. Examples include:

• Ketoconazole and Itraconazole (antifungals).
• Clarithromycin and Erythromycin (antibiotics).
• Ritonavir (HIV medication).

• Tamoxifen: Cinacalcet may reduce the effectiveness of tamoxifen because tamoxifen requires the CYP2D6 enzyme to be converted into its active form (endoxifen).
• Codeine/Tramadol: Similar to tamoxifen, these pain medications require CYP2D6 to be converted into their active forms. Cinacalcet may make these painkillers less effective.

• High-Fat Meals: As noted, taking Cinacalcet with a high-fat meal increases absorption by up to 81%. To ensure consistent dosing, you should always take the medication in the same way (either always with food or always without, though with food is preferred for nausea management).
• Grapefruit Juice: Grapefruit is a known inhibitor of CYP3A4. While not as potent as some medications, it can still increase Cinacalcet levels and should be avoided.

• St. John's Wort: This herbal supplement induces CYP3A4, which may speed up the metabolism of Cinacalcet, making it less effective.
• Calcium Supplements: While it seems counterintuitive, taking large amounts of calcium supplements without medical supervision can interfere with the titration of Cinacalcet. Only take calcium if specifically directed by your nephrologist.
• Vitamin D: High doses of Vitamin D (calcitriol) can raise calcium levels, potentially masking the effects of Cinacalcet.

Cinacalcet does not typically interfere with standard laboratory test methodologies. However, its physiological effect of lowering PTH and calcium will obviously be reflected in lab results. It is important that blood for PTH testing is drawn at a consistent time relative to your Cinacalcet dose (usually just before the next dose) to ensure accurate monitoring.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. A complete medication review is necessary to avoid dangerous interactions.

There is one primary absolute contraindication for the initiation of Cinacalcet therapy:

1. 1Hypocalcemia: Cinacalcet must NEVER be started if a patient's serum calcium level is below the lower limit of the normal range (typically <8.4 mg/dL). Because the drug's primary action is to lower calcium, starting it in a patient who is already hypocalcemic can lead to severe tetany, seizures, or cardiac arrest.
2. 2Hypersensitivity: Patients with a known severe allergy to Cinacalcet hydrochloride or any of the inactive ingredients (such as pregelatinized starch, microcrystalline cellulose, or povidone) should not take this medication. Symptoms of hypersensitivity may include angioedema (swelling of the face/throat) or severe rash.

These are conditions where the drug may be used, but only with extreme caution and frequent monitoring:

• Seizure Disorders: Because hypocalcemia lowers the seizure threshold, patients with epilepsy or a history of seizures are at higher risk. The benefit of PTH control must be weighed against the risk of inducing a seizure.
• Moderate to Severe Hepatic Impairment: Since the liver is the primary site of metabolism, patients with Child-Pugh Class B or C liver disease will have significantly higher drug exposure. Dose titration must be extremely slow.
• Heart Failure and Arrhythmias: Patients with a history of congestive heart failure or a 'long QT' interval on an ECG require baseline and periodic cardiac monitoring, as electrolyte shifts can worsen these conditions.

There is no known cross-sensitivity between Cinacalcet and other major drug classes (like penicillins or sulfonamides). However, patients who have had a reaction to other calcimimetics (like Etelcalcetide) should be monitored closely for similar allergic responses, although the chemical structures of these two drugs are different.

> Important: Your healthcare provider will evaluate your complete medical history, including your latest blood work, before prescribing Cinacalcet. Always report any history of low calcium or seizures.

Cinacalcet is currently classified as a medication with limited human data regarding pregnancy. In animal studies (rats and rabbits), no evidence of teratogenicity (birth defects) was found at doses significantly higher than the human equivalent. However, in pregnant rats, the drug did cross the placental barrier and caused a decrease in fetal body weight and lower serum calcium levels in the offspring.

Because of the lack of well-controlled studies in humans, Cinacalcet should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is generally not used in fertility treatments. If you become pregnant while taking Cinacalcet, notify your doctor immediately.

It is not known whether Cinacalcet is excreted in human milk. Animal studies have shown that Cinacalcet is excreted in the milk of lactating rats, with a high milk-to-plasma ratio. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants (specifically severe hypocalcemia), a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

The safety and efficacy of Cinacalcet in pediatric patients have not been established for the treatment of secondary hyperparathyroidism or parathyroid carcinoma. Following the death of a 14-year-old patient in a clinical trial due to severe hypocalcemia, the FDA has been extremely cautious. While some pediatric trials have explored its use for rare mineral disorders, it is not standard practice and is considered 'off-label' and high-risk in most pediatric settings.

Clinical studies of Cinacalcet included a significant number of subjects aged 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. However, the elderly are more prone to polypharmacy (taking multiple medications), which increases the risk of CYP2D6-mediated drug interactions. Additionally, the risk of falls due to dizziness (a potential side effect) is a greater concern in this population.

Cinacalcet is specifically indicated for patients with end-stage renal disease (ESRD) on dialysis. No dosage adjustment is required based on the degree of renal impairment. It is important to note that Cinacalcet is not effectively removed by hemodialysis or peritoneal dialysis due to its high protein binding and large volume of distribution.

In patients with moderate to severe hepatic impairment, the half-life of Cinacalcet is prolonged and plasma levels are higher. Specifically, the AUC (total exposure) was 2.4 times higher in patients with moderate impairment and 4.2 times higher in those with severe impairment. Healthcare providers will monitor serum calcium and PTH levels even more frequently in these patients during dose titration.

> Important: Special populations require individualized medical assessment. Always inform your specialist about your pregnancy status or any history of liver disease.

Cinacalcet is an allosteric modulator of the calcium-sensing receptor (CaSR). The CaSR is a Class C G-protein coupled receptor. Its primary role in the parathyroid gland is to sense changes in extracellular ionized calcium and regulate the secretion of parathyroid hormone (PTH) accordingly.

Cinacalcet binds to the transmembrane domain of the CaSR. This binding does not activate the receptor directly but rather increases the sensitivity of the receptor to the calcium already present in the blood. By shifting the concentration-response curve for calcium to the left, Cinacalcet allows the receptor to be activated at lower calcium concentrations. Once activated, the receptor triggers an intracellular signaling cascade (involving phospholipase C and increased intracellular calcium) that inhibits the exocytosis of PTH from the chief cells of the parathyroid gland.

The effect of Cinacalcet on PTH levels is rapid. Following a single oral dose, PTH levels begin to fall within 30 minutes, reaching a nadir (lowest point) approximately 2 to 4 hours post-dose. Serum calcium levels follow this decline, though more slowly, typically reaching a nadir 12 to 24 hours after administration. There is a clear dose-response relationship; higher doses lead to greater suppression of PTH. Tolerance does not typically develop, meaning the drug remains effective over long-term use provided the underlying disease state is managed.

| Parameter | Value |

|---|---|

| Bioavailability | 20-25% (Fasted), up to 81% (with high-fat meal) |

| Protein Binding | 93% to 97% |

| Half-life | 30 to 40 hours (Terminal) |

| Tmax | 2 to 6 hours |

| Metabolism | Hepatic (CYP3A4, 2D6, 1A2) |

| Excretion | Renal 80%, Fecal 15% |

• Molecular Formula: C22H22F3N·HCl
• Molecular Weight: 393.9 g/mol
• Solubility: Soluble in methanol and 95% ethanol; slightly soluble in water.
• Chemical Structure: Cinacalcet is a naphthalene derivative. Specifically, it is N-[1-(R)-(-)-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propylamine hydrochloride. It exists as a white to off-white, non-hygroscopic crystalline powder.

Cinacalcet belongs to the therapeutic class of Calcimimetics. It is currently the only oral agent in this class. Its primary therapeutic area is Mineral and Bone Disorder (MBD) in the context of Chronic Kidney Disease. Related medications include Etelcalcetide (an intravenous calcimimetic) and various Vitamin D analogs like Calcitriol or Paricalcitol, though the latter work through a different mechanism (the Vitamin D receptor).